MEXATE

Post-LOE

methotrexate sodium

Bristol Myers Squibb

ANDAINJECTIONINJECTABLE

Approved

Sep 1979

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MEXATE (methotrexate sodium) by Bristol Myers Squibb is reductase. Approved for refractory non-hodgkin lymphoma, part of a combination chemotherapy regimen, refractory non-hodgkin lymphomas and 6 more indications. First approved in 1979.

Drug data last refreshed 3d ago

Mechanism of Action

reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively…

Indications (7)

refractory non-Hodgkin lymphoma part of a combination chemotherapy regimen

Worked on MEXATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.